A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Inclusion Criteria:

• Male or female participants must be ≥ 18 years old.

• Mean seated SBP on automated office blood pressure measurement (AOBPM) ≥ 140 mmHg atScreening.

• Fulfil at least 1 of the following 2 criteria:

1. uHTN subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensivemedications, from different therapeutic classes (at least one must be adiuretic), at maximum tolerated dose in the judgement of the Investigator.

2. rHTN subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensivemedications, from different therapeutic classes (at least one must be adiuretic), at maximum tolerated dose in the judgement of the Investigator.

• Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening.

• Serum potassium (K+) level ≥ 3.5 and < 5.0 mmol/L at Screening.• Mean seated SBP onAOBPM ≥ 135 mmHg at Baseline.

Exclusion Criteria:

• Mean seated SBP on AOBPM ≥ 170 mmHg.

• Mean seated DBP on AOBPM ≥ 105 mmHg.

• Serum sodium level (Na+) < 135 mmol/L at Screening.

• Has the following known secondary causes of hypertension: renal artery stenosis,uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism,pheochromocytoma, Cushing's syndrome, aortic coarctation.

• NYHA functional heart failure class IV at Screening.